Publisher
Springer Science and Business Media LLC
Reference55 articles.
1. Thurlow JS, Joshi M, Yan G, et al. Global epidemiology of end-stage kidney disease and disparities in kidney replacement therapy. Am J Nephrol. 2021;52(2):98–107.
2. Vanholder R, Annemans L, Brown E, et al. Reducing the costs of chronic kidney disease while delivering quality health care: a call to action. Nat Rev Nephrol. 2017;13(7):393–409.
3. Chadban S, Arıcı M, Power A, et al. Projecting the economic burden of chronic kidney disease at the patient level (Inside CKD): a microsimulation modelling study. eClinicalMedicine.
4. Chertow GM, Correa-Rotter R, Eckardt K-U, et al. Projecting the clinical burden of chronic kidney disease at the patient level (Inside CKD): a microsimulation modelling study. eClinicalMedicine.
5. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–46.